Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - epoetin lambda, quantity: 1000 iu - injection, solution - excipient ingredients: sodium hydroxide; water for injections; dibasic sodium phosphate dihydrate; polysorbate 80; dilute hydrochloric acid; monobasic sodium phosphate dihydrate; glycine; sodium chloride - treatment of patients with symptomatic or transfusion requiring anaemia associated with chronic renal failure to improve their quality of life by improving energy levels, exercise performance, fatigue and sleep patterns and by reducing the need for blood transfusions.. treatment of anaemia in patients with nonmyeloid malignancies, where anaemia develops as a result of concomitantly administered chemotherapy, and where blood transfusion is not considered appropriate. adult patients with mild to moderate anaemia (haemoglobin > 100 to less than or equal to 130g/l) scheduled for elective surgery with an expected moderate blood loss (two to four units or 900 to 1,800ml) to reduce exposure to allogeneic blood transfusion and to facilitate erythropoietic recovery.. augment autologous blood collection and to limit the decline in haemoglobin in anaemic adult patients who are scheduled for major elective surgery and who are not expected to predeposit their complete perioperative blood needs.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - epoetin lambda, quantity: 6000 iu - injection, solution - excipient ingredients: monobasic sodium phosphate dihydrate; dibasic sodium phosphate dihydrate; polysorbate 80; dilute hydrochloric acid; water for injections; sodium hydroxide; glycine; sodium chloride - treatment of patients with symptomatic or transfusion requiring anaemia associated with chronic renal failure to improve their quality of life by improving energy levels, exercise performance, fatigue and sleep patterns and by reducing the need for blood transfusions.. treatment of anaemia in patients with nonmyeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy, where blood transfusion is not considered appropriate. adult patients with mild to moderate anaemia (haemoglobin > 100 to less than or equal to 130g/l) scheduled for elective surgery with an expected moderate blood loss (two to four units or 900 to 1,800ml) to reduce exposure to allogeneic blood transfusion and to facilitate erythropoietic recovery.. augment autologous blood collection and to limit the decline in haemoglobin in anaemic adult patients who are scheduled for major elective surgery and who are not expected to predeposit their complete perioperative blood needs.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - epoetin lambda, quantity: 4000 iu - injection, solution - excipient ingredients: water for injections; sodium chloride; glycine; polysorbate 80; dilute hydrochloric acid; sodium hydroxide; monobasic sodium phosphate dihydrate; dibasic sodium phosphate dihydrate - treatment of patients with symptomatic or transfusion requiring anaemia associated with chronic renal failure to improve their quality of life by improving energy levels, exercise performance, fatigue and sleep patterns and by reducing the need for blood transfusions.. treatment of anaemia in patients with nonmyeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy, and where blood transfusion is not considered appropriate. adult patients with mild to moderate anaemia (haemoglobin > 100 to less than or equal to 130g/l) scheduled for elective surgery with an expected moderate blood loss (two to four units or 900 to 1,800ml) to reduce exposure to allogeneic blood transfusion and to facilitate erythropoietic recovery.. augment autologous blood collection and to limit the decline in haemoglobin in anaemic adult patients who are scheduled for major elective surgery and who are not expected to predeposit their complete perioperative blood needs.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - epoetin lambda, quantity: 10000 iu - injection, solution - excipient ingredients: sodium chloride; monobasic sodium phosphate dihydrate; dilute hydrochloric acid; glycine; dibasic sodium phosphate dihydrate; polysorbate 80; water for injections; sodium hydroxide - treatment of patients with symptomatic or transfusion requiring anaemia associated with chronic renal failure to improve their quality of life by improving energy levels, exercise performance, fatigue and sleep patterns and by reducing the need for blood transfusions.. treatment of anaemia in patients with nonmyeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy, and where blood transfusion is not considered appropriate. adult patients with mild to moderate anaemia (haemoglobin > 100 to less than or equal to 130g/l) scheduled for elective surgery with an expected moderate blood loss (two to four units or 900 to 1,800ml) to reduce exposure to allogeneic blood transfusion and to facilitate erythropoietic recovery.. augment autologous blood collection and to limit the decline in haemoglobin in anaemic adult patients who are scheduled for major elective surgery and who are not expected to predeposit their complete perioperative blood needs.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - epoetin lambda, quantity: 8000 iu - injection, solution - excipient ingredients: dibasic sodium phosphate dihydrate; dilute hydrochloric acid; sodium chloride; glycine; water for injections; polysorbate 80; sodium hydroxide; monobasic sodium phosphate dihydrate - treatment of patients with symptomatic or transfusion requiring anaemia associated with chronic renal failure to improve their quality of life by improving energy levels, exercise performance, fatigue and sleep patterns and by reducing the need for blood transfusions.. treatment of anaemia in patients with nonmyeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy, and where blood transfusion is not considered appropriate. adult patients with mild to moderate anaemia (haemoglobin > 100 to less than or equal to 130g/l) scheduled for elective surgery with an expected moderate blood loss (two to four units or 900 to 1,800ml) to reduce exposure to allogeneic blood transfusion and to facilitate erythropoietic recovery.. augment autologous blood collection and to limit the decline in haemoglobin in anaemic adult patients who are scheduled for major elective surgery and who are not expected to predeposit their complete perioperative blood needs.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - epoetin lambda, quantity: 2000 iu - injection, solution - excipient ingredients: monobasic sodium phosphate dihydrate; dibasic sodium phosphate dihydrate; water for injections; sodium chloride; glycine; sodium hydroxide; dilute hydrochloric acid; polysorbate 80 - treatment of patients with symptomatic or transfusion requiring anaemia associated with chronic renal failure to improve their quality of life by improving energy levels, exercise performance, fatigue and sleep patterns and by reducing the need for blood transfusions.. treatment of anaemia in patients with nonmyeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy, and where blood transfusion is not considered appropriate. adult patients with mild to moderate anaemia (haemoglobin > 100 to less than or equal to 130g/l) scheduled for elective surgery with an expected moderate blood loss (two to four units or 900 to 1,800ml) to reduce exposure to allogeneic blood transfusion and to facilitate erythropoietic recovery.. augment autologous blood collection and to limit the decline in haemoglobin in anaemic adult patients who are scheduled for major elective surgery and who are not expected to predeposit their complete perioperative blood needs.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - epoetin alfa, quantity: 40000 iu/ml - injection, solution - excipient ingredients: glycine; polysorbate 80; monobasic sodium phosphate; water for injections; dibasic sodium phosphate dihydrate; sodium chloride - eprex is indicated for the treatment of patients with symptomatic or transfusion requiring anaemia associated with chronic renal failure to improve their quality of life by improving energy levels, exercise performance, fatigue and sleep patterns and by reducing the need for blood transfusions. eprex is also indicated for the prevention and treatment of anaemia in adult patients with non-myeloid malignancies, where anaemia is anticipated to develop and develops as a result of concomitantly administered chemotherapy. eprex is indicated to decrease the need for transfusion in patients who will continue to receive concomitant chemotherapy for a minimum of two months. eprex is also indicated in adult patients with mild-to-moderate anaemia (haemoglobin >10 <=13 g/dl) scheduled for elective surgery with an expected moderate blood loss (2-4 units to 900 to 1800ml) to reduce exposure to allogenic blood transfusion and to facilitate erythropoietic recovery. eprex is also indicated to augment autologous blood collection and to limit the decline in haemoglobin in anaemic adults patients who are scheduled for major elective surgery and who are not expected to predeposit their complete perioperative blood needs.

Պանամա - անգլերեն - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

roche diagnostics gmbh - metoxipolietilenglicol-epoetina beta - metoxipolietilenglicol-epoetina beta....50 mcg

Պանամա - անգլերեն - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

roche diagnostics gmbh - metoxipolietilenglicol-epoetina beta - metoxipolietilenglicol-epoetina beta....75 mcg

Պանամա - անգլերեն - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

roche diagnostics gmbh - metoxipolietilenglicol-epoetina beta - metoxipolietilenglicol-epoetina beta....200 mg